Found 19 Small Cell Lung Cancer trials
A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 23922 A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of H
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
VIGOR
Prospective, single arm, non-randomized, open label trial evaluating the pathologic response of soft tissue ablated with pulse electric fields in patients with non-small cell lung cancer (NSCLC) who may be candidates for resection following standard of care neoadjuvant use of checkpoint inhibitor treatment plus platinum doublet chemotherapy.
A Clinical Study of Aliya Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment of Advanced Cancer
Phase 4
The Investigation Device Exemption (IDE) study will evaluate the safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
NRG-LU008 Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.
To compare the overall survival in patients with stage II-IIIC inoperable nodepositive non-small cell lung cancer (NSCLC) after image guided, motion-managed conventional radiotherapy to the primary tumor and nodal metastases (Arm 1) or after image guided, motion-managed stereotactic body radiation therapy (SBRT) to the primary tumor followed by conventionally fractionated …
UPCC 05519: Single-Arm Study Of Carboplatin Weekly Taxane And Ramucirumab In Advanced NSCLC After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab
Phase 2
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
This study aims to provide much-needed data regarding how to optimally treat vulnerable older adults with metastatic NSCLC.
UPCC 12523: Real-world efficacy and safety, patterns of resistance and clinical progression among patients with Non-Small Cell Lung Cancer harboring EGFR exon 20 insertion mutations: An ATOMIC Analysis
This study is a retrospective and prospective medical record review of patients with NSCLC harboring EGFR ex20ins mutations treated at cancer centers participating in ATOMIC.
UPCC 20522 A Phase 1 Open-Label Study of Patritumab Deruxtecan in Combination with Osimertinib in Subjects with Locally Advanced or metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
11 - 19 of 19
- 1
- 2
